Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Inhibitors of human indoleamine 2,3-dioxygenase identified with a target-based screen in yeast.

Vottero E, Balgi A, Woods K, Tugendreich S, Melese T, Andersen RJ, Mauk AG, Roberge M.

Biotechnol J. 2006 Mar;1(3):282-8.

PMID:
16897708
2.

Inhibitors of indoleamine 2,3-dioxygenase: a review of novel patented lead compounds.

Di Pucchio T, Danese S, De Cristofaro R, Rutella S.

Expert Opin Ther Pat. 2010 Feb;20(2):229-50. doi: 10.1517/13543770903512974. Review.

PMID:
20100004
3.

Indoleamine 2,3-dioxygenase, an emerging target for anti-cancer therapy.

Liu X, Newton RC, Friedman SM, Scherle PA.

Curr Cancer Drug Targets. 2009 Dec;9(8):938-52. Review.

PMID:
20025603
4.

Tumor immune escape mediated by indoleamine 2,3-dioxygenase.

Zamanakou M, Germenis AE, Karanikas V.

Immunol Lett. 2007 Aug 15;111(2):69-75. Epub 2007 Jul 2. Review.

PMID:
17644189
5.

Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors.

Muller AJ, Malachowski WP, Prendergast GC.

Expert Opin Ther Targets. 2005 Aug;9(4):831-49. Review.

PMID:
16083346
6.

Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway.

Ball HJ, Yuasa HJ, Austin CJ, Weiser S, Hunt NH.

Int J Biochem Cell Biol. 2009 Mar;41(3):467-71. doi: 10.1016/j.biocel.2008.01.005. Epub 2008 Jan 11. Review.

PMID:
18282734
7.

Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease.

Macchiarulo A, Camaioni E, Nuti R, Pellicciari R.

Amino Acids. 2009 Jul;37(2):219-29. doi: 10.1007/s00726-008-0137-3. Epub 2008 Jul 9. Review.

PMID:
18612775
8.

Indoleamine 2,3-dioxygenase in immune suppression and cancer.

Muller AJ, Prendergast GC.

Curr Cancer Drug Targets. 2007 Feb;7(1):31-40. Review.

PMID:
17305476
9.

Marrying immunotherapy with chemotherapy: why say IDO?

Muller AJ, Prendergast GC.

Cancer Res. 2005 Sep 15;65(18):8065-8. Review.

10.

Manipulation of indoleamine 2,3 dioxygenase; a novel therapeutic target for treatment of diseases.

Tan PH, Bharath AK.

Expert Opin Ther Targets. 2009 Aug;13(8):987-1012. doi: 10.1517/14728220903018940. Review.

PMID:
19534572
11.

Oxidation of L-tryptophan in biology: a comparison between tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase.

Rafice SA, Chauhan N, Efimov I, Basran J, Raven EL.

Biochem Soc Trans. 2009 Apr;37(Pt 2):408-12. doi: 10.1042/BST0370408. Review.

PMID:
19290871
12.

Research progress of indoleamine 2,3-dioxygenase inhibitors.

Jiang T, Sun Y, Yin Z, Feng S, Sun L, Li Z.

Future Med Chem. 2015;7(2):185-201. doi: 10.4155/fmc.14.151. Review.

PMID:
25686005
13.

Marine natural products and other derivatives as potent indoleamine 2,3-dioxygenase inhibitors.

Delfourne E.

Mini Rev Med Chem. 2012 Sep 1;12(10):988-96. Review.

PMID:
22512584
14.

Molecules in focus: indoleamine 2,3-dioxygenase.

King NJ, Thomas SR.

Int J Biochem Cell Biol. 2007;39(12):2167-72. Epub 2007 Jan 20. Review.

PMID:
17320464
15.

Clinical relevance of indoleamine 2,3-dioxygenase for alloimmunity and transplantation.

Brandacher G, Margreiter R, Fuchs D.

Curr Opin Organ Transplant. 2008 Feb;13(1):10-5. doi: 10.1097/MOT.0b013e3282f3df26. Review.

PMID:
18660700
16.

Implications of IFN-gamma-mediated tryptophan catabolism on solid organ transplantation.

Brandacher G, Margreiter R, Fuchs D.

Curr Drug Metab. 2007 Apr;8(3):273-82. Review.

PMID:
17430115
17.

Chronic immune activation underlies morbid obesity: is IDO a key player?

Brandacher G, Hoeller E, Fuchs D, Weiss HG.

Curr Drug Metab. 2007 Apr;8(3):289-95. Review.

PMID:
17430117
18.

Manipulation of indoleamine 2,3-dioxygenase (IDO) for clinical transplantation: promises and challenges.

Quan J, Tan PH, MacDonald A, Friend PJ.

Expert Opin Biol Ther. 2008 Nov;8(11):1705-19. doi: 10.1517/14712598.8.11.1705 . Review.

PMID:
18847306
19.

Pharmacological targeting of IDO-mediated tolerance for treating autoimmune disease.

Penberthy WT.

Curr Drug Metab. 2007 Apr;8(3):245-66. Review.

PMID:
17430113
20.

Indoleamine 2,3-dioxygenase in materno-fetal interaction.

Sedlmayr P.

Curr Drug Metab. 2007 Apr;8(3):205-8. Review.

PMID:
17430108

Supplemental Content

Support Center